Ruofei Yu

519 total citations
9 papers, 405 citations indexed

About

Ruofei Yu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Ruofei Yu has authored 9 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Ruofei Yu's work include Lung Cancer Treatments and Mutations (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Ruofei Yu is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Ruofei Yu collaborates with scholars based in China, United States and Taiwan. Ruofei Yu's co-authors include Jianxin Lyu, Qi Wang, Zhiyun Xu, Encheng Li, Yitong Xu, Zhao Sun, Xiancheng Li, Zhe Guo, Zheng Zhang and Jianpeng Chen and has published in prestigious journals such as ACS Applied Materials & Interfaces, Science Advances and BMC Medicine.

In The Last Decade

Ruofei Yu

9 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruofei Yu China	8	191	141	118	78	46	9	405
Qiongxi Pan China	10	65 0.3×	67 0.5×	262 2.2×	12 0.2×	106 2.3×	10	445
Zhen Shi China	14	52 0.3×	137 1.0×	386 3.3×	118 1.5×	5 0.1×	36	569
Benjamin K. Eschle United States	9	66 0.3×	45 0.3×	201 1.7×	45 0.6×	87 1.9×	14	370
Rania Harati United Arab Emirates	13	45 0.2×	83 0.6×	325 2.8×	79 1.0×	7 0.2×	25	531
Guorun Fan China	11	47 0.2×	22 0.2×	138 1.2×	64 0.8×	18 0.4×	16	299
Morayo G. Adebiyi United States	8	123 0.6×	87 0.6×	108 0.9×	17 0.2×	6 0.1×	10	334
Evangelia Pantazaka Greece	13	18 0.1×	89 0.6×	253 2.1×	39 0.5×	29 0.6×	22	402
Xianmei Pan China	12	32 0.2×	32 0.2×	235 2.0×	150 1.9×	32 0.7×	16	480
Kuan Ning China	8	29 0.2×	80 0.6×	300 2.5×	22 0.3×	30 0.7×	10	382
Charles Saby France	9	26 0.1×	61 0.4×	112 0.9×	13 0.2×	19 0.4×	14	262

Countries citing papers authored by Ruofei Yu

Since Specialization

Citations

This map shows the geographic impact of Ruofei Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruofei Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruofei Yu more than expected).

Fields of papers citing papers by Ruofei Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruofei Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruofei Yu. The network helps show where Ruofei Yu may publish in the future.

Co-authorship network of co-authors of Ruofei Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruofei Yu. A scholar is included among the top collaborators of Ruofei Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruofei Yu. Ruofei Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Zhang, Pei, Yang Du, Hua Bai, et al.. (2022). Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Medicine. 20(1). 435–435. 26 indexed citations

Li, Weihua, Hua Bai, Jianchun Duan, et al.. (2022). Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non–small cell lung cancer. Thoracic Cancer. 13(21). 2951–2959. 6 indexed citations

Yu, Ruofei, Hua Bai, Jiefei Han, et al.. (2021). TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. Translational Oncology. 14(9). 101163–101163. 17 indexed citations

Han, Jiefei, Ruofei Yu, Jianchun Duan, et al.. (2021). Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers. Science Advances. 7(21). 10 indexed citations

Zhang, Pei, Jianchun Duan, Hua Bai, et al.. (2020). Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer. Thoracic Cancer. 12(1). 30–39. 14 indexed citations

Yu, Ruofei, et al.. (2020). Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis‐inhibiting pathway. Thoracic Cancer. 12(1). 128–132. 8 indexed citations

Du, Qiang, Ruofei Yu, Yan Dong, et al.. (2018). Significance of tumor‐associated autoantibodies in the early diagnosis of lung cancer. The Clinical Respiratory Journal. 12(6). 2020–2028. 35 indexed citations

Xu, Zhiyun, Encheng Li, Zhe Guo, et al.. (2016). Design and Construction of a Multi-Organ Microfluidic Chip Mimicking the in vivo Microenvironment of Lung Cancer Metastasis. ACS Applied Materials & Interfaces. 8(39). 25840–25847. 214 indexed citations

Chen, Jianpeng, Yi Luan, Ruofei Yu, et al.. (2014). Transient receptor potential (TRP) channels, promising potential diagnostic and therapeutic tools for cancer. BioScience Trends. 8(1). 1–10. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact